{"entity":{"id":"akt1-e17k","kind":"biomarker","name":"AKT1 E17K mutation","aka":["AKT1 E17K","AKT1 mutation","E17K","AKT1-mutant"],"tldr":"AKT1 E17K is a single hotspot mutation, in about 3 to 5 percent of hormone-receptor-positive breast cancers, that switches on the AKT kinase directly. It is one of the three alterations that qualify a patient for capivasertib.","summary":"The E17K substitution in the pleckstrin homology domain sends AKT1 to the membrane without PIP3. Capivasertib (Truqap) is labelled with fulvestrant for HR-positive HER2-negative advanced breast cancer with one or more PIK3CA, AKT1 or PTEN alterations as detected by an FDA-approved test (CAPItello-291); FoundationOne CDx carries the three-gene claim. AKT1 E17K also appears in endometrial and rarer cancers, where it is a trial marker only.","asOf":"2026-09-23","links":[{"label":"TRUQAP prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf"}],"tags":["biomarker","pi3k"],"related":["pik3ca-hotspot-mutation","pten-alteration"],"cancers":["breast-hr-positive","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["capivasertib","foundationone-cdx"],"companies":[],"institutions":[],"pathways":[],"terms":["hyperglycaemia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"akt","measurement":"sequencing-variant","scoringRule":{"text":"The AKT1 c.49G>A (p.E17K) substitution by sequencing of tumour tissue or plasma, reported with PIK3CA and PTEN as the capivasertib selection set.","quote":"PIK3CA/AKT1/PTEN alterations","source":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools","sourceLabel":"FDA: List of FDA-Authorized Companion Diagnostic Devices"},"thresholds":[{"value":"AKT1 alteration (with PIK3CA and PTEN as the qualifying set)","drugId":"capivasertib","cancerId":"breast-hr-positive","regulator":"FDA","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf","quote":"with one or more PIK3CA/AKT1/PTEN -alterations as detected by an FDA-approved test","status":"current"}],"tests":["foundationone-cdx","foundationone-liquid-cdx","guardant360-cdx","tempus-xt"],"assays":["foundationone-cdx-panel"],"companionDiagnostics":[{"device":"FoundationOne CDx","maker":"Foundation Medicine","companyId":"foundation-medicine","drugs":["capivasertib","fulvestrant"],"indication":"Breast Cancer - Tissue","pma":"P170019/S048 (11/16/2023)","source":"https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools"}],"forPatient":"An AKT1 E17K result in hormone-receptor-positive breast cancer qualifies you for capivasertib with fulvestrant once hormone therapy has stopped working, the same as a PIK3CA mutation or PTEN loss would. Alpelisib and inavolisib are not approved for AKT1 mutations on their own."},"route":"/biomarkers/akt1-e17k/","neighbours":{"biomarker":[{"id":"pik3ca-hotspot-mutation","kind":"biomarker","name":"PIK3CA mutation","route":"/biomarkers/pik3ca-hotspot-mutation/"},{"id":"pten-alteration","kind":"biomarker","name":"PTEN alteration (sequencing) and PTEN loss (IHC)","route":"/biomarkers/pten-alteration/"}],"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"capivasertib","kind":"drug","name":"Capivasertib","route":"/drugs/capivasertib/"},{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/"}],"term":[{"id":"hyperglycaemia","kind":"term","name":"Hyperglycaemia (PI3K/AKT inhibitor class effect)","route":"/terms/hyperglycaemia/"}],"target":[{"id":"akt","kind":"target","name":"AKT","route":"/targets/akt/"}]}}